Evidence map›Paper›PMID 21307132›Full record

ArticleCancer research2011

Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.

Terry G Coursey, Peter W Chen, Jerry Y Niederkorn

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Terry G CourseyDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. jerry.niederkorn@utsouthwestern.edu
Peter W Chen
Jerry Y Niederkorn
The University of Texas Southwestern Medical Center · US

Funding

TRANSPLANT AND TUMOR REJECTION PROCESSES WITHIN THE EYER01EY005631 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI NIEDERKORN, JERRY · 1985 to 2015
$5.8M
Core Grant for Vision ResearchP30EY020799 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI NIEDERKORN, JERRY · 2010 to 2016
$4.1M
INFRASTRUCTIRE DEVELOPMENT GRANT FOR CORNEA RESEARCHR24EY016664 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI PETROLL, W MATTHEW · 2005 to 2009
$1.2M
NEI NIH HHS EY005631NEI NIH HHS EY016664NEI NIH HHS EY020799NEI NIH HHS P30 EY020799NEI NIH HHS R01 EY005631NEI NIH HHS R24 EY016664
6 · The paper itself

Abstract

Although intraocular tumors reside in an immune privileged site, some tumors are rejected nonetheless. For example, intraocular adenovirus-induced (Ad5E1; adenovirus type 5 early region 1) tumors are rejected in syngeneic C57BL/6 mice by one of two pathways. One pathway leads to extensive necrosis of innocent bystander cells and culminates in destruction of the eye, a condition called phthisis. The second pathway is characterized by piecemeal tumor cell death that rids the eye of the tumor while preserving the architecture and function of the eye. To study the mechanisms of phthisical tumor rejection, we isolated a cell clone-designated clone 2.1 that consistently undergoes rejection in a phthisical manner. CD4(+) T cells and macrophages were required for phthisical rejection of intraocular clone 2.1 tumors and M1 macrophages were involved in mediating tumor rejection. In vitro and in vivo inhibition of iNOS (inducible nitric oxide synthase) abolished macrophage-mediated killing of tumor cells and rejection of intraocular tumors. A role for M1 macrophages was further supported by investigations showing that intraocular tumors grew progressively in IFN-γ KO (knockout) mice. Studies in mice deficient in TNF-α, TNF receptor-1, or TNF receptor-2 revealed that although TNF-α was not needed for tumor rejection, it was required for the development of necrotizing inflammation and phthisis of tumor-bearing eyes. Together, our findings suggest new strategies to successfully eliminate ocular tumors while preserving the integrity of the eye.

Indexed as

AdenoviridaeAdenovirus E1 ProteinsAnimalsCell Transformation, ViralEnzyme InhibitorsEye NeoplasmsMiceMice, Inbred C57BLMice, KnockoutMice, SCIDNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IIT-LymphocytesTransfectionTumor Necrosis Factor-alphaAdenovirus E1 ProteinsEnzyme InhibitorsNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IINos2 protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID21307132
PMCPMC3108159
OpenAlexW2112559573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.